Pennant Group 경영진
경영진 기준 점검 3/4
Pennant Group CEO는 Brent Guerisoli, Aug2022 에 임명되었습니다 의 임기는 3.5 년입니다. 총 연간 보상은 $3.74M, 11.9% 급여 및 88.1% 보너스(회사 주식 및 옵션 포함)로 구성됩니다. 는 $3.91M 가치에 해당하는 회사 주식의 0.28% 직접 소유합니다. 경영진과 이사회의 평균 재임 기간은 3.8 년과 6.1 년입니다.
핵심 정보
Brent Guerisoli
최고경영자
US$3.7m
총 보수
| CEO 급여 비율 | 11.89% |
| CEO 재임 기간 | 4yrs |
| CEO 지분 보유율 | 0.3% |
| 경영진 평균 재임 기간 | 3.8yrs |
| 이사회 평균 재임 기간 | 6.1yrs |
최근 경영진 업데이트
Recent updates
내러티브 업데이트 • Aug 14
PNTG: Home Health And Hospice Expansion Plus AI Investments Are Expected To Support Upside
Pennant Group’s updated analyst price target has moved higher by about $2.83 to roughly $46.33, with analysts pointing to stronger Q2 performance, improving home health and hospice margins, and sector demand trends as key supports for the change. Analyst Commentary Recent research on Pennant Group focuses on how Q2 execution, margin trends, and sector demand expectations feed into updated valuation views.
내러티브 업데이트 • Jul 30
PNTG: Sector Demand Tailwinds And Index Inclusion Will Support Future Upside
The Pennant Group analyst price target has moved from $40 to $49 as analysts point to updated assumptions on revenue growth, profit margins, and sector demand trends to support the higher valuation range. Analyst Commentary on Pennant Group Recent research updates on Pennant Group highlight a more constructive tone from bullish analysts who are revisiting their valuation work ahead of upcoming earnings.내러티브 업데이트 • Jul 16
PNTG: Sector Tailwinds And Tech Investments Are Expected To Support Steady Upside
The analyst price target for Pennant Group has increased from $40.83 to $43.50. Analysts attribute this change to supportive sector trends in healthcare services, anticipated demand for care, and ongoing investments in growth and technology, which are key drivers behind their updated assumptions.내러티브 업데이트 • Jul 02
PNTG: Q1 Senior Health Momentum And Expansion Are Expected To Support Upside
The Pennant Group analyst price target has increased by about $2.70 to roughly $40.83. Analysts attribute the change to updated views on fair value, profitability, and valuation multiples, following recent research from firms that raised their targets by $2, $3, and $6.분석 기사 • Jun 21
Pennant Group (PNTG) Stock Could Be 12.4% Undervalued After Q1 Revenue Beat
Pennant Group (PNTG) is back in focus after reporting quarterly revenue growth of more than 35% year over year, alongside higher net profit, beating analyst expectations and drawing fresh attention to its decentralized operating model. See our latest analysis for Pennant Group. The recent Q1 surprise and focus on Pennant Group’s decentralized model come against a backdrop of building momentum, with a year to date share price return of 20.16% and a 3 year total shareholder return of 174.55%,...
내러티브 업데이트 • Jun 18
PNTG: Senior Health Momentum And Hartford Partnership Will Drive Future Stock Upside
Analysts have raised their price target on Pennant Group stock by a combined $11, citing updated views on the company supported by recent research from multiple firms. Analyst Commentary Recent research on Pennant Group stock points to a more nuanced view than the headline price target increases suggest.내러티브 업데이트 • Jun 04
PNTG: Senior Living Expansion And Higher P/E Assumptions Will Support Future Upside Potential
Narrative Update on Pennant Group The analyst fair value estimate for Pennant Group has moved from $36.00 to $40.00, with analysts pointing to updated assumptions around revenue growth, profit margins, and a higher future P/E multiple as key drivers for the new price targets. Analyst Commentary Recent Street research around Pennant Group has centered on updated price targets that reflect revised assumptions for revenue, profitability, and the P/E multiple applied to future earnings.내러티브 업데이트 • May 06
PNTG: AMED Asset Integration Will Drive Future Earnings Realization Potential
Analysts have raised Pennant Group's fair value estimate by $2 to $36, reflecting updated Street price targets and ongoing confidence that the company can gradually realize earnings potential from the AMED assets over time. Analyst Commentary Recent Street research has centered on how quickly Pennant Group can translate the AMED assets into consistent earnings and whether current valuation fairly reflects that path.내러티브 업데이트 • Apr 22
PNTG: AMED Assets Are Expected To Underpin Future Upside Despite 2026 Guidance
Narrative Update Analysts have nudged Pennant Group's price target higher, with recent moves such as RBC Capital's increase to $41 from $39 contributing to a modest lift in estimated fair value and future P/E assumptions. Analyst Commentary Recent Street research around Pennant Group centers on how the market should weigh its guidance against longer term earnings potential from AMED assets and what that could imply for valuation.내러티브 업데이트 • Apr 07
PNTG: AMED Assets Will Drive Future Upside Despite Softer 2026 Guidance
Narrative Update on Pennant Group Analysts have lifted Pennant Group's price targets into a $38 to $41 range, citing long-term earnings potential tied to AMED assets. They also hold a relatively favorable view of Medicare Advantage exposure, even with mixed near term guidance and sector headwinds.내러티브 업데이트 • Mar 24
PNTG: AMED Assets Will Drive Future Upside Despite Softer 2026 Outlook
Narrative Update Analysts have recently nudged Pennant Group's average price target higher into the high $30s to low $40s range, citing confidence that the company can gradually realize earnings potential from the AMED assets, even though 2026 adjusted EBITDA guidance sits below earlier expectations. Analyst Commentary Recent research updates show analysts adjusting expectations for Pennant Group while still assigning higher price targets.내러티브 업데이트 • Mar 10
PNTG: AMED Earnings Potential Will Offset Tempered Outlook For 2026
Pennant Group's updated fair value estimate edges up to about $37.83 from $37.50 as analysts lift price targets into the high $30s and low $40s, pointing to confidence in long term earnings potential from AMED assets, despite more tempered revenue growth assumptions and a slightly lower future P/E multiple. Analyst Commentary Recent research points to a generally constructive view on Pennant Group, with price targets shifting into the high $30s and low $40s range.내러티브 업데이트 • Feb 24
PNTG: Fair Outlook Will Weigh Medicare Advantage Constructiveness Against Policy And Margin Risks
Analysts have raised their price target on Pennant Group from $31 to $38, with the higher fair value of $34 linked to updated views on revenue growth, profit margin, and a higher future P/E multiple in the context of a relatively constructive stance on Medicare Advantage. Analyst Commentary Even with the higher price target range and a constructive stance on Medicare Advantage, some commentary around Pennant Group points to risks that are worth keeping in mind as you weigh the setup.내러티브 업데이트 • Feb 10
PNTG: Home Health Reimbursement Upside Will Drive Future Upside Optionality
Narrative Update on Pennant Group Analysts have raised their price target on Pennant Group to $38 from $31, citing potential upside from home health reimbursement rates even under conservative assumptions, and noting that recent regulatory concerns are already reflected in the shares. Analyst Commentary Bullish Takeaways Bullish analysts see room for upside in the shares even when they assume conservative home health reimbursement rates, which they view as already reflected in the current valuation.분석 기사 • Jan 28
With EPS Growth And More, Pennant Group (NASDAQ:PNTG) Makes An Interesting Case
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...내러티브 업데이트 • Jan 26
PNTG: Home Health Reimbursement Upside Will Drive Future Upside Optionality
Analysts have lifted their price target on Pennant Group to US$38 from US$31, citing potential upside from home health reimbursement rates even under conservative assumptions. They also view the current valuation as offering attractive optionality if reimbursement trends improve.내러티브 업데이트 • Jan 11
PNTG: Raised Fair Value Framework Will Rely On Home Health Reimbursement Outcomes
Analysts have raised their price target on Pennant Group from $31 to $38, citing updated fair value assumptions of $37.50, a higher future P/E estimate of 27.33, and expectations for stronger revenue growth, while also accounting for a slightly higher discount rate and a modestly lower profit margin outlook. Analyst Commentary Recent Street research provides a mix of optimism and caution around Pennant Group, with updated targets and ratings reflecting changing views on reimbursement, valuation, and sector risk.내러티브 업데이트 • Dec 16
PNTG Will Balance Reimbursement Upside Against Policy And Margin Execution Risks
Pennant Group's analyst price target has been raised from $28 to $30 per share, as analysts highlight upside from potential home health reimbursement improvements despite conservative base case assumptions. Analyst Commentary While the latest target increase underscores growing optimism around home health reimbursement, not all market observers share an unequivocally bullish stance.분석 기사 • Aug 09
The Pennant Group, Inc. Just Missed EPS By 18%: Here's What Analysts Think Will Happen Next
NasdaqGS:PNTG 1 Year Share Price vs Fair Value Explore Pennant Group's Fair Values from the Community and select yours...분석 기사 • Jul 17
Earnings Tell The Story For The Pennant Group, Inc. (NASDAQ:PNTG)
The Pennant Group, Inc.'s ( NASDAQ:PNTG ) price-to-earnings (or "P/E") ratio of 32.2x might make it look like a strong...분석 기사 • Jun 28
Does Pennant Group (NASDAQ:PNTG) Have A Healthy Balance Sheet?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...분석 기사 • May 16
Pennant Group's (NASDAQ:PNTG) Earnings Are Weaker Than They Seem
The Pennant Group, Inc.'s ( NASDAQ:PNTG ) stock was strong after they recently reported robust earnings. However, our...분석 기사 • Apr 15
Is The Pennant Group, Inc. (NASDAQ:PNTG) Trading At A 33% Discount?
Key Insights Pennant Group's estimated fair value is US$38.66 based on 2 Stage Free Cash Flow to Equity Pennant Group...분석 기사 • Mar 01
With EPS Growth And More, Pennant Group (NASDAQ:PNTG) Makes An Interesting Case
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...분석 기사 • Dec 21
Why Investors Shouldn't Be Surprised By The Pennant Group, Inc.'s (NASDAQ:PNTG) P/E
With a price-to-earnings (or "P/E") ratio of 44.5x The Pennant Group, Inc. ( NASDAQ:PNTG ) may be sending very bearish...분석 기사 • Nov 14
Investors Shouldn't Be Too Comfortable With Pennant Group's (NASDAQ:PNTG) Earnings
Unsurprisingly, The Pennant Group, Inc.'s ( NASDAQ:PNTG ) stock price was strong on the back of its healthy earnings...분석 기사 • Nov 12
Is The Pennant Group, Inc. (NASDAQ:PNTG) Trading At A 34% Discount?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Pennant Group fair value estimate is US$50.94 Current share...분석 기사 • Oct 06
Is Now The Time To Put Pennant Group (NASDAQ:PNTG) On Your Watchlist?
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...
새로운 내러티브 • Sep 16
Critical Acquisitions And Leadership Drive Remarkable Growth In Home Health Sector
Emphasis on expansion and acquisitions, such as the Muir Home Health joint venture, aims to significantly boost revenue and market share.분석 기사 • Sep 14
Investors Still Waiting For A Pull Back In The Pennant Group, Inc. (NASDAQ:PNTG)
The Pennant Group, Inc.'s ( NASDAQ:PNTG ) price-to-earnings (or "P/E") ratio of 53.9x might make it look like a strong...분석 기사 • Aug 26
Does Pennant Group (NASDAQ:PNTG) Have A Healthy Balance Sheet?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...분석 기사 • May 14
Here's Why Pennant Group (NASDAQ:PNTG) Can Manage Its Debt Responsibly
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...CEO 보수 분석
| 날짜 | 총 보수 | 급여 | 회사 수익 |
|---|---|---|---|
| Jun 30 2026 | n/a | n/a | US$32m |
| Mar 31 2026 | n/a | n/a | US$30m |
| Dec 31 2025 | US$4m | US$445k | US$30m |
| Sep 30 2025 | n/a | n/a | US$27m |
| Jun 30 2025 | n/a | n/a | US$27m |
| Mar 31 2025 | n/a | n/a | US$25m |
| Dec 31 2024 | US$3m | US$415k | US$23m |
| Sep 30 2024 | n/a | n/a | US$21m |
| Jun 30 2024 | n/a | n/a | US$19m |
| Mar 31 2024 | n/a | n/a | US$16m |
| Dec 31 2023 | US$2m | US$363k | US$13m |
| Sep 30 2023 | n/a | n/a | US$13m |
| Jun 30 2023 | n/a | n/a | US$13m |
| Mar 31 2023 | n/a | n/a | US$7m |
| Dec 31 2022 | US$2m | US$296k | US$7m |
| Sep 30 2022 | n/a | n/a | US$1m |
| Jun 30 2022 | n/a | n/a | -US$3m |
| Mar 31 2022 | n/a | n/a | US$3m |
| Dec 31 2021 | US$760k | US$268k | US$3m |
| Sep 30 2021 | n/a | n/a | US$9m |
| Jun 30 2021 | n/a | n/a | US$12m |
| Mar 31 2021 | n/a | n/a | US$14m |
| Dec 31 2020 | US$2m | US$228k | US$16m |
| Sep 30 2020 | n/a | n/a | US$8m |
| Jun 30 2020 | n/a | n/a | US$5m |
| Mar 31 2020 | n/a | n/a | US$4m |
| Dec 31 2019 | US$605k | US$55k | US$3m |
보상 대 시장: Brent의 총 보수(USD3.74M)는 US 시장에서 비슷한 규모 기업의 평균(USD5.10M) 수준입니다.
보상과 수익: Brent의 보상은 지난 1년 동안 20% 이상 증가했습니다.
CEO
Brent Guerisoli (45 yo)
4yrs
재임 기간
US$3,739,476
보수
Mr. Brent J. Guerisoli is Chairman of the Board at The Pennant Group, Inc. from January 1, 2025 and has been its Chief Executive Officer since August 01, 2022. Mr. Guerisoli serves as a Director at The Pen...
리더십 팀
| 이름 | 직위 | 재임 기간 | 보수 | 지분 |
|---|---|---|---|---|
| CEO & Chairman | 4yrs | US$3.74m | 0.28% $ 3.9m | |
| President & COO | 7.6yrs | US$3.39m | 0.44% $ 6.0m | |
| Chief Financial Officer | 3.3yrs | US$2.66m | 0.049% $ 666.7k | |
| Executive VP | 3.6yrs | US$1.80m | 0.053% $ 723.5k | |
| Chief Clinical Officer | no data | US$1.83m | 0.045% $ 619.4k | |
| President of Pinnacle Senior Living LLC | no data | 데이터 없음 | 데이터 없음 |
3.8yrs
평균 재임 기간
44yo
평균 나이
경험이 풍부한 관리: PNTG의 경영진은 경험이 있음으로 간주됩니다(평균 재임 3.8 년).
이사회 구성원
| 이름 | 직위 | 재임 기간 | 보수 | 지분 |
|---|---|---|---|---|
| CEO & Chairman | 3.5yrs | US$3.74m | 0.28% $ 3.9m | |
| Independent Director | 5.3yrs | US$251.69k | 0.29% $ 4.0m | |
| Lead Independent Director | 7.6yrs | US$313.43k | 0.17% $ 2.3m | |
| Independent Director | 6.8yrs | US$259.19k | 0.51% $ 7.0m | |
| Independent Director | 7.6yrs | US$236.69k | 2.2% $ 30.3m | |
| Independent Director | 7.6yrs | US$242.19k | 0.13% $ 1.7m | |
| Independent Director | 1.3yrs | US$123.47k | 0.66% $ 9.1m | |
| Independent Director | 4.6yrs | US$248.69k | 0.11% $ 1.5m |
6.1yrs
평균 재임 기간
63yo
평균 나이
경험이 풍부한 이사회: PNTG의 이사회는 경험이 있음으로 간주됩니다(평균 재임 6.1 년).
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/08/16 06:11 |
| 종가 | 2026/08/14 00:00 |
| 수익 | 2026/06/30 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
The Pennant Group, Inc.는 8명의 분석가가 다루고 있습니다. 이 중 7명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Brian Tanquilut | Jefferies LLC |
| Michael Wiederhorn | Oppenheimer & Co. Inc. |
| Benjamin Hendrix | RBC Capital Markets |